Primary sclerosing cholangitis (PSC) is a progressive scarring of the liver's bile ducts. According to current estimates, between 5 and 16 in every 100,000 people have PSC. The symptoms of PSC ...

The global primary sclerosing cholangitis (PSC) market is on an impressive growth trajectory, with forecasts estimating a market valuation of USD 314.26 million by 2033. This robust expansion is ...

Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that currently has no approved treatment options. Results from the phase 2 ELMWOOD ...

1 CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes, T Snir, R Greenman, R Aricha, I Vaknin, M Frankel ...

today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive liver ...

Esperion announced the expansion of its development portfolio with a new program aimed at treating primary sclerosing cholangitis (PSC), a rare liver disease. The company confirmed the ...

Primary sclerosing cholangitis (PSC) is a rare progressive liver disease that damages bile ducts and significantly increases the risk of bile duct cancer, particularly a type called ...

For more information on the press release, click on the following link : Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant ...

investigated whether or not tacrolimus is indeed safe and efficacious in patients with primary sclerosing cholangitis (PSC). Sixteen PSC patients with serum alkaline phosphatase levels at least 1. ...

There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam. Dr. Falk ...

as a first-in-class treatment for primary sclerosing cholangitis (PSC) and other fibro-inflammatory diseases. The comprehensive proteomic analyses we are presenting at EASL 2025 indicate that ...